1INCY logo

Incyte CorporationBIT:1INCY Stock Report

Market Cap €20.2b
Share Price
n/a
1Y76.8%
7D2.0%
1D1.3%
Portfolio Value
​
View

Incyte Corporation

BIT:1INCY Stock Report

Market Cap: €20.2b

Incyte (1INCY) Stock Overview

A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. More details

1INCY fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance6/6
Financial Health6/6
Dividends0/6

Rewards

Price-To-Earnings ratio (16.5x) is below the Italian market (17.6x)

Earnings grew by 6631.4% over the past year

Trading at good value compared to peers and industry

Risk Analysis

Earnings are forecast to decline by an average of 15.2% per year for the next 3 years


1INCY Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW502,015 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
502,015 investors already sharing narratives
View all narratives

Incyte Corporation Competitors

Price History & Performance

Summary of share price highs, lows and changes for Incyte
Historical stock prices
Current Share PriceUS$102.85
52 Week HighUS$103.75
52 Week LowUS$65.14
Beta0.76
1 Month Change12.38%
3 Month Change27.16%
1 Year Change76.84%
3 Year Change80.95%
5 Year Change49.53%
Change since IPO21.89%

Recent News & Updates

Recent updates

Shareholder Returns

1INCYIT BiotechsIT Market
7D2.0%2.4%1.8%
1Y76.8%48.5%25.2%

Return vs Industry: 1INCY exceeded the Italian Biotechs industry which returned 49.4% over the past year.

Return vs Market: 1INCY exceeded the Italian Market which returned 26.8% over the past year.

Price Volatility

Is 1INCY's price volatile compared to industry and market?
1INCY volatility
1INCY Average Weekly Movement5.4%
Biotechs Industry Average Movement7.9%
Market Average Movement4.7%
10% most volatile stocks in IT Market8.4%
10% least volatile stocks in IT Market3.0%

Stable Share Price: 1INCY has not had significant price volatility in the past 3 months compared to the Italian market.

Volatility Over Time: 1INCY's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19912,844Bill Meurywww.incyte.com

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma.

Incyte Corporation Fundamentals Summary

How do Incyte's earnings and revenue compare to its market cap?
1INCY fundamental statistics
Market cap€20.23b
Earnings (TTM)€1.25b
Revenue (TTM)€4.70b
16.5x
P/E Ratio
4.4x
P/S Ratio

Is 1INCY overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1INCY income statement (TTM)
RevenueUS$5.36b
Cost of RevenueUS$2.53b
Gross ProfitUS$2.83b
Other ExpensesUS$1.40b
EarningsUS$1.43b

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)7.17
Gross Margin52.77%
Net Profit Margin26.71%
Debt/Equity Ratio0%

How did 1INCY perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/07 12:42
End of Day Share Price 2026/07/07 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Incyte Corporation is covered by 45 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Thomas RussoBaird
Peter LawsonBarclays